Government-Owned Inventions; Availability for Licensing, 10280-10281 [2010-4758]
Download as PDF
<![CDATA[
erowe on DSK5CLS3C1PROD with NOTICES
10280
Federal Register / Vol. 75, No. 43 / Friday, March 5, 2010 / Notices
Information Collection: Intermediate
Care Facility (ICF) for the Mentally
Retarded (MR) or Persons with Related
Conditions Survey Report Form and
Supporting Regulations at 42 CFR
442.30, 483.410, 483.420, 483.440,
483.450 and 483.460; Use: This survey
form is needed to ensure ICF/MR
provider and client characteristics are
available and updated annually for the
Federal government’s Online Survey
Certification and Reporting (OSCAR)
system. It is required for the provider to
fill out at the time of the annual
recertification or initial certification
survey conducted by the State Medicaid
agency. The team leader for the State
survey team must review and approve
the completed form before completion
of the survey. The State Medicaid
survey agency is responsible for
transferring the 3070 information into
OSCAR. Form Number: CMS–3070
(OMB#: 0938–0062); Frequency:
Reporting—Yearly; Affected Public:
Private Sector: Business or other forprofits and Not-for-profit institutions;
Number of Respondents: 6,437; Total
Annual Responses: 6,437; Total Annual
Hours: 19,311. (For policy questions
regarding this collection contact Kelley
Tinsley at 410–786–6664. For all other
issues call 410–786–1326.)
2. Type of Information Collection
Request: Extension of a currently
approved collection; Title of
Information Collection: Annual Early
and Periodic Screening, Diagnostic and
Treatment (EPSDT) Services
Participation Report; Form Number:
CMS–416 (OMB#: 0938–0354); Use:
States are required to submit an annual
report on the provision of EPSDT
services pursuant to section
1902(a)(43)(D) of the Social Security
Act. These reports provide CMS with
data necessary to assess the
effectiveness of State EPSDT programs,
to determine a State’s results in
achieving its participation goal and to
respond to inquiries. Respondents are
State Medicaid Agencies. The data is
due April 1 of every year so States need
to have the form and instructions as
soon as possible in order to report
timely. Frequency: Yearly; Affected
Public: State, Tribal and Local
governments; Number of Respondents:
56; Total Annual Responses: 56; Total
Annual Hours: 504. (For policy
questions regarding this collection
contact Cindy Ruff at 410–786–5916.
For all other issues call 410–786–1326.)
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS Web Site
address at https://www.cms.hhs.gov/
PaperworkReductionActof1995, or E-
VerDate Nov<24>2008
14:45 Mar 04, 2010
Jkt 220001
mail your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov, or call the
Reports Clearance Office on (410) 786–
1326.
To be assured consideration,
comments and recommendations for the
proposed information collections must
be received by the OMB desk officer at
the address below, no later than 5 p.m.
on April 5, 2010.
OMB, Office of Information and
Regulatory Affairs.
Attention: CMS Desk Officer.
Fax Number: (202) 395–6974.
E-mail:
OIRA_submission@omb.eop.gov.
Dated: February 24, 2010.
Michelle Shortt,
Director, Regulations Development Group,
Office of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2010–4313 Filed 3–4–10; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Monoclonal Antibody to Mouse TollLike Receptor 3 (TLR3) Extracellular
Domain
Description of Invention: The best
available antibody for labeling cells
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
expressing mouse TLR3 is now available
for licensing. It is a rat IgG2a
monoclonal antibody that was generated
to the extracellular domain of mouse
TLR3 and specifically binds mouse
TLR3 in permeabilized cells. TLR3 is
located in endosomes and recognizes
double-stranded RNA, a molecular
signature of many viruses. This
antibody would be of interest to anyone
studying TLR3 distribution and
localization in studies related to innate
immunity and dendritic cell function.
Applications:
• Fluorescence-Activated Cell Sorting
(FACS).
• Immunofluorescence.
• Immunocytochemistry.
Inventors: David M. Segal, Yan Wang,
Ivett Jelinek (NCI).
Related Publication: Unpublished.
Patent Status: HHS Reference No. E–
038–2010/0—Research Tool. Patent
protection is not being pursued for this
technology.
Licensing Status: This technology is
available as a research tool (hybridoma)
under a Biological Materials License.
Licensing Contact: Steve Standley,
Ph.D.; 301–435–4074;
sstand@od.nih.gov.
Haptoglobin for Control of the Blood
Pressure Response to Plasma Free
Hemoglobin
Description of Invention: Release of
hemoglobin into the blood is a central
pathophysiologic event contributing to
morbidity and mortality in chronic and
acute hemolytic anemias and severe
malaria. These toxicities arise from
hemoglobin-related scavenging of nitric
oxide, a blood vessel vasodilator, and
peroxidative chain reactions that lead to
damage of the surrounding tissues.
Animal models have demonstrated both
an attenuation of the hypertensive
response due to nitric oxide scavenging
and a prevention of peroxidative
toxicity. Compartmentalization of
hemoglobin, rather than short-lived
nitric oxide-based drugs, may represent
a new therapeutic paradigm in
countering the pathophysiological side
effects associated with free hemoglobin.
This technology identifies
haptoglobin and haptoglobin mimetics
as potential therapeutics for high blood
pressure and intravascular toxicity due
to release of hemoglobin from red blood
cells. It provides a novel process in
which free hemoglobin is
compartmentalized within the
haptoglobin molecule. Therapeutic
proof-of-principle has been
demonstrated for this technology in dog
and guinea pig models.
Potential Applications and
Advantages:
E:\FR\FM\05MRN1.SGM
05MRN1
Federal Register / Vol. 75, No. 43 / Friday, March 5, 2010 / Notices
erowe on DSK5CLS3C1PROD with NOTICES
• A therapeutic for high blood
pressure and intravascular toxicity
resulting from free hemoglobin in the
blood (as associated with hemolytic
anemias such as sickle cell disease,
paroxysmal nocturnal hemoglobinuria,
and thalassemia, as well as cerebral
malaria).
• Compartmentalization of
hemoglobin may minimize toxicities
associated with cell-free hemoglobin, in
contrast to currently available nitric
oxide-based drugs which seek to
counterbalance but not minimize these
toxicities.
Development Status: Pre-clinical
stage.
Inventors: Abdu I. Alayash (FDA) et
al.
Publication: FS Boretti et al.
Sequestration of extracellular
hemoglobin within a haptoglobin
complex decreases its hypertensive and
oxidative effects in dogs and guinea
pigs. J Clin Invest. 2009
Aug;119(8):2271–2280. [PubMed:
19620788]
Patent Status: U.S. Provisional
Application No. 61/226,602 filed 17 Jul
2009 (HHS Reference No. E–256–2009/
0–US–01)
Licensing Status: Available for
licensing.
Licensing Contact: Fatima Sayyid,
M.H.P.M.; 301–435–4521;
Fatima.Sayyid@nih.hhs.gov.
A Biomarker and Therapeutic Target
for Ovarian Cancer
Description of Invention: This
technology provides methods of
diagnosing or treating certain ovarian
cancers using STAMP, a steroid
cofactor.
According to the American Cancer
Society, ovarian cancer is the ninth
most common cancer in the United
States, but is the fifth most deadly, with
an estimated 14,600 deaths in 2009; the
10-year survival rate for this cancer is
less than 40 percent. The majority of
ovarian cancer cases are diagnosed at
late-stage disease, due to the difficulty
in detecting this cancer in its early
stages, when symptoms are subtle.
There are currently no effective
methods for early-stage diagnosis of
ovarian cancer. Diagnosis is usually
made through a combination of physical
examination, ultrasound imaging, and a
blood test for the tumor marker CA–125.
The CA–125 test only returns a true
positive result for about 50% of earlystage ovarian cancers, and may be
elevated in other conditions not related
to cancer, so it is not an adequate early
detection tool when used alone.
The inventors previously discovered
STAMP, a steroid cofactor that
VerDate Nov<24>2008
14:45 Mar 04, 2010
Jkt 220001
modulates glucocorticoid receptormediated gene induction and
repression. The inventors have now
shown that STAMP mRNA levels are
elevated in ovarian cancer samples,
including early-stage cancers. They have
also found that in a subset of ovarian
cancer cell lines, introduction of
STAMP siRNAs slows cell proliferation.
These findings suggest that STAMP may
be useful as a biomarker to detect early
stage cancer in ovarian tissues, and is
also promising as a therapeutic target for
a subset of ovarian cancers.
Applications:
• Development of an early-stage
diagnostic test for ovarian cancer.
• Development of an siRNA-based
therapy for ovarian cancer.
Development Status: Discovery stage.
Market: Ovarian cancer is the fifth
most-deadly cancer in the United States,
and over 21,000 new U.S. cases were
diagnosed in 2009.
Inventors: S. Stoney Simons et al.
(NIDDK).
Related Publications: In preparation.
Patent Status: U.S. Provisional
Application No. 61/185,503 filed 09 Jun
2009 (HHS Reference No. E–226–2009/
0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Tara Kirby, PhD;
301–435–4426; tarak@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Diabetes and
Digestive and Kidney Disease Steroid
Hormones Section is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize STAMP, a steroid
cofactor. Please contact S. Stoney
Simons at steroids@helix.nih.gov for
more information.
Conditional V2 Vasopressin Receptor
Mutant Mice as a Model To Study Xlinked Nephrogenic Diabetes Insipidus
(XNDI)
Description of Invention: X-linked
nephrogenic diabetes insipidus (XNDI)
is a severe kidney disease caused by
inactivating mutations in the V2
vasopressin receptor (V2R) gene that
result in the loss of renal urineconcentrating ability. At present, no
specific pharmacological therapy has
been developed for XNDI, primarily due
to the lack of suitable animal models.
This technology provides a unique and
viable animal model of XNDI. NIH
investigators have generated mice in
which the V2R gene could be
conditionally deleted during adulthood
by administration of 4–OH-tamoxifen.
Radioligand-binding studies confirmed
the lack of V2R-binding sites in kidneys
PO 00000
Frm 00078
Fmt 4703
Sfmt 9990
10281
following 4–OH-tamoxifen treatment,
and further analysis indicated that upon
V2R deletion, adult mice displayed all
characteristic symptoms of XNDI,
including polyuria, polydipsia, and
resistance to the antidiuretic actions of
vasopressin.
Gene expression analysis suggested
that activation of renal EP4 PGE2
receptors might compensate for the lack
of renal V2R activity in XNDI mice.
Strikingly, both acute and chronic
treatment of the mutant mice with a
selective EP4 receptor agonist greatly
reduced all major manifestations of
XNDI, including changes in renal
morphology. These physiological
improvements were most likely due to
a direct action on EP4 receptors
expressed on collecting duct cells.
These findings illustrate the usefulness
of V2R mutant mice for elucidating and
testing new strategies for the potential
treatment of humans with XNDI.
¨
Inventors: Jurgen Wess et al. (NIDDK)
Publication: Li JH, Chou CL, Li B,
Gavrilova O, Eisner C, Schnermann J,
Anderson SA, Deng CX, Knepper MA,
Wess J. A selective EP4 PGE2 receptor
agonist alleviates disease in a new
mouse model of X-linked nephrogenic
diabetes insipidus. J Clin Invest. 2009
Oct 1;119(10):3115–3126. [PubMed:
19729836]
Patent Status: HHS Reference Nos. E–
174–2009/0 & E–175–2009/0—Research
Tool. Patent protection is not being
pursued for this technology.
Licensing Status: Available for
licensing under a Biological Materials
License Agreement.
Licensing Contact: Suryanarayana
(Sury) Vepa, Ph.D., J.D.; 301–435–5020;
vepas@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Diabetes and
Digestive and Kidney Diseases,
Laboratory of Bioorganic Chemistry,
Molecular Signalling Section, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize this technology. Please
¨
contact Dr. Jurgen Wess at
jwess@helix.nih.gov for more
information.
Dated: March 1, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–4758 Filed 3–4–10; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\05MRN1.SGM
05MRN1
]]>Agencies
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Pages 10280-10281]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-4758]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Monoclonal Antibody to Mouse Toll-Like Receptor 3 (TLR3) Extracellular
Domain
Description of Invention: The best available antibody for labeling
cells expressing mouse TLR3 is now available for licensing. It is a rat
IgG2a monoclonal antibody that was generated to the extracellular
domain of mouse TLR3 and specifically binds mouse TLR3 in permeabilized
cells. TLR3 is located in endosomes and recognizes double-stranded RNA,
a molecular signature of many viruses. This antibody would be of
interest to anyone studying TLR3 distribution and localization in
studies related to innate immunity and dendritic cell function.
Applications:
Fluorescence-Activated Cell Sorting (FACS).
Immunofluorescence.
Immunocytochemistry.
Inventors: David M. Segal, Yan Wang, Ivett Jelinek (NCI).
Related Publication: Unpublished.
Patent Status: HHS Reference No. E-038-2010/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status: This technology is available as a research tool
(hybridoma) under a Biological Materials License.
Licensing Contact: Steve Standley, Ph.D.; 301-435-4074;
sstand@od.nih.gov.
Haptoglobin for Control of the Blood Pressure Response to Plasma Free
Hemoglobin
Description of Invention: Release of hemoglobin into the blood is a
central pathophysiologic event contributing to morbidity and mortality
in chronic and acute hemolytic anemias and severe malaria. These
toxicities arise from hemoglobin-related scavenging of nitric oxide, a
blood vessel vasodilator, and peroxidative chain reactions that lead to
damage of the surrounding tissues. Animal models have demonstrated both
an attenuation of the hypertensive response due to nitric oxide
scavenging and a prevention of peroxidative toxicity.
Compartmentalization of hemoglobin, rather than short-lived nitric
oxide-based drugs, may represent a new therapeutic paradigm in
countering the pathophysiological side effects associated with free
hemoglobin.
This technology identifies haptoglobin and haptoglobin mimetics as
potential therapeutics for high blood pressure and intravascular
toxicity due to release of hemoglobin from red blood cells. It provides
a novel process in which free hemoglobin is compartmentalized within
the haptoglobin molecule. Therapeutic proof-of-principle has been
demonstrated for this technology in dog and guinea pig models.
Potential Applications and Advantages:
[[Page 10281]]
A therapeutic for high blood pressure and intravascular
toxicity resulting from free hemoglobin in the blood (as associated
with hemolytic anemias such as sickle cell disease, paroxysmal
nocturnal hemoglobinuria, and thalassemia, as well as cerebral
malaria).
Compartmentalization of hemoglobin may minimize toxicities
associated with cell-free hemoglobin, in contrast to currently
available nitric oxide-based drugs which seek to counterbalance but not
minimize these toxicities.
Development Status: Pre-clinical stage.
Inventors: Abdu I. Alayash (FDA) et al.
Publication: FS Boretti et al. Sequestration of extracellular
hemoglobin within a haptoglobin complex decreases its hypertensive and
oxidative effects in dogs and guinea pigs. J Clin Invest. 2009
Aug;119(8):2271-2280. [PubMed: 19620788]
Patent Status: U.S. Provisional Application No. 61/226,602 filed 17
Jul 2009 (HHS Reference No. E-256-2009/0-US-01)
Licensing Status: Available for licensing.
Licensing Contact: Fatima Sayyid, M.H.P.M.; 301-435-4521;
Fatima.Sayyid@nih.hhs.gov.
A Biomarker and Therapeutic Target for Ovarian Cancer
Description of Invention: This technology provides methods of
diagnosing or treating certain ovarian cancers using STAMP, a steroid
cofactor.
According to the American Cancer Society, ovarian cancer is the
ninth most common cancer in the United States, but is the fifth most
deadly, with an estimated 14,600 deaths in 2009; the 10-year survival
rate for this cancer is less than 40 percent. The majority of ovarian
cancer cases are diagnosed at late-stage disease, due to the difficulty
in detecting this cancer in its early stages, when symptoms are subtle.
There are currently no effective methods for early-stage diagnosis
of ovarian cancer. Diagnosis is usually made through a combination of
physical examination, ultrasound imaging, and a blood test for the
tumor marker CA-125. The CA-125 test only returns a true positive
result for about 50% of early-stage ovarian cancers, and may be
elevated in other conditions not related to cancer, so it is not an
adequate early detection tool when used alone.
The inventors previously discovered STAMP, a steroid cofactor that
modulates glucocorticoid receptor-mediated gene induction and
repression. The inventors have now shown that STAMP mRNA levels are
elevated in ovarian cancer samples, including early-stage cancers. They
have also found that in a subset of ovarian cancer cell lines,
introduction of STAMP siRNAs slows cell proliferation. These findings
suggest that STAMP may be useful as a biomarker to detect early stage
cancer in ovarian tissues, and is also promising as a therapeutic
target for a subset of ovarian cancers.
Applications:
Development of an early-stage diagnostic test for ovarian
cancer.
Development of an siRNA-based therapy for ovarian cancer.
Development Status: Discovery stage.
Market: Ovarian cancer is the fifth most-deadly cancer in the
United States, and over 21,000 new U.S. cases were diagnosed in 2009.
Inventors: S. Stoney Simons et al. (NIDDK).
Related Publications: In preparation.
Patent Status: U.S. Provisional Application No. 61/185,503 filed 09
Jun 2009 (HHS Reference No. E-226-2009/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Tara Kirby, PhD; 301-435-4426;
tarak@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Diabetes and Digestive and Kidney Disease Steroid Hormones Section is
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
STAMP, a steroid cofactor. Please contact S. Stoney Simons at
steroids@helix.nih.gov for more information.
Conditional V2 Vasopressin Receptor Mutant Mice as a Model To Study X-
linked Nephrogenic Diabetes Insipidus (XNDI)
Description of Invention: X-linked nephrogenic diabetes insipidus
(XNDI) is a severe kidney disease caused by inactivating mutations in
the V2 vasopressin receptor (V2R) gene that result in the loss of renal
urine-concentrating ability. At present, no specific pharmacological
therapy has been developed for XNDI, primarily due to the lack of
suitable animal models. This technology provides a unique and viable
animal model of XNDI. NIH investigators have generated mice in which
the V2R gene could be conditionally deleted during adulthood by
administration of 4-OH-tamoxifen. Radioligand-binding studies confirmed
the lack of V2R-binding sites in kidneys following 4-OH-tamoxifen
treatment, and further analysis indicated that upon V2R deletion, adult
mice displayed all characteristic symptoms of XNDI, including polyuria,
polydipsia, and resistance to the antidiuretic actions of vasopressin.
Gene expression analysis suggested that activation of renal EP4
PGE2 receptors might compensate for the lack of renal V2R activity in
XNDI mice. Strikingly, both acute and chronic treatment of the mutant
mice with a selective EP4 receptor agonist greatly reduced all major
manifestations of XNDI, including changes in renal morphology. These
physiological improvements were most likely due to a direct action on
EP4 receptors expressed on collecting duct cells. These findings
illustrate the usefulness of V2R mutant mice for elucidating and
testing new strategies for the potential treatment of humans with XNDI.
Inventors: J[uuml]rgen Wess et al. (NIDDK)
Publication: Li JH, Chou CL, Li B, Gavrilova O, Eisner C,
Schnermann J, Anderson SA, Deng CX, Knepper MA, Wess J. A selective EP4
PGE2 receptor agonist alleviates disease in a new mouse model of X-
linked nephrogenic diabetes insipidus. J Clin Invest. 2009 Oct
1;119(10):3115-3126. [PubMed: 19729836]
Patent Status: HHS Reference Nos. E-174-2009/0 & E-175-2009/0--
Research Tool. Patent protection is not being pursued for this
technology.
Licensing Status: Available for licensing under a Biological
Materials License Agreement.
Licensing Contact: Suryanarayana (Sury) Vepa, Ph.D., J.D.; 301-435-
5020; vepas@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Diabetes and Digestive and Kidney Diseases, Laboratory of Bioorganic
Chemistry, Molecular Signalling Section, is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize this
technology. Please contact Dr. J[uuml]rgen Wess at jwess@helix.nih.gov
for more information.
Dated: March 1, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-4758 Filed 3-4-10; 8:45 am]
BILLING CODE 4140-01-P
